Daily Physical Activity in Myelomeningocele

Marmara University

Status: Completed

Conditions: Physical Activity

Treatments: Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)

Study type: Observational

Funder types: Other

Identifiers

NCT04186338

09.2017.168

Details and patient eligibility

About

Obesity is getting more common and challenging to treat in children and adolescents with myelomeningocele. Therefore, it is becoming more important to determine daily physical activity in these patients. Daily walking performance and average steps per day in patients with low lumbar and sacral level myelomeningocele are shown to not differ from healthy controls. Step counts can not reflect all torsional accelerations associated with daily living activities. Omnidirectional accelerometers provide all types of body movement outputs and give detailed parameters of physical activity level and energy expenditure. There is no data about energy expenditure and physical activity level of the patients with myelomeningocele in daily routine. This study aims to quantify energy expenditure and physical activity of children and adolescents with low lumbar and sacral level myelomeningocele.

Full description

Children and adolescents with low lumbar and sacral level myelomeningocele, and age-, sex-, and BMI-matched controls were included. Omnidirectional accelerometer monitor (Actical®) was used to assess activity energy expenditure and daily durations spent in sedentary, light activity and moderate to vigorous physical activity (MVPA).

Enrollment: 20 patients

Sex: All

Ages: 6 to 16 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients diagnosed myelomeningocele with the neurological level between L5 and S3
• Patients aged between 6 and 16 years
• Independent ambulatory patients without an assistive device or braces

Exclusion criteria

• Presence of disorders other than myelomeningocele that affect physical activity or exercise (e.g. rheumatic disease, cardiovascular disease)
• Unable to wear omnidirectional accelerometer monitor (Actical®, Philips Respironics) for five consecutive days

Trial design

20 participants in 2 patient groups

Patients with myelomeningocele

Description:

Patients diagnosed myelomeningocele with the neurological level between L5 and S3

Treatment:

Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)

Healthy controls

Description:

age-, sex-, and body mass index-matched healthy controls

Treatment:

Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)